HUTCHMED HK$4.17 billion IPO and primary listing
Davis Polk advised the joint global coordinators and the joint bookrunners on the primary listing and initial public offering of HUTCHMED (China) Limited on the Hong Kong Stock Exchange. The gross proceeds from the offering amounted to approximately HK$4.17 billion (US$537 million) prior to the exercise of the over-allotment option.
HUTCHMED (China) Limited is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. The ADSs of HUTCHMED (China) Limited are listed for trading on the Nasdaq and its ordinary shares are listed on the London AIM.
The Davis Polk corporate team included partners James C. Lin and Xuelin (Steve) Wang and registered foreign lawyers Jennifer Liu and Mendtuvshin (Mendee) Enkhtaivan. Counsel Alon Gurfinkel and associates Omer Harel and Summer Xia provided tax advice. Members of the Davis Polk team are based in the Hong Kong and London offices.